Patents by Inventor Juan I. Luengo

Juan I. Luengo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thrombopoietin mimetics
    Patent number: 7241783
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: July 10, 2007
    Assignees: SmithKline Beecham Corporation, Ligand Pharmaceutical
    Inventors: Kevin J. Duffy, Juan I. Luengo, Stephen G. Miller, Julian Jenkins, Alan T. Price, Antony N. Shaw
  • Thrombopoietin mimetics
    Patent number: 7160870
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: January 9, 2007
    Assignees: SmithKline Beecham Corporation, Glaxo Group Limited
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
  • Thrombopoietin mimetics
    Patent number: 6875786
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: April 5, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw
  • Naphthimidazole derivatives and their use as thrombopoietin mimetics
    Patent number: 6858630
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: February 22, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I. Luengo, Kevin J. Duffy, Alan T. Price, Lihua Zhang
  • Thrombopoietin mimetics
    Publication number: 20040077855
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: August 28, 2003
    Publication date: April 22, 2004
    Inventors: Kevin J. Duffy, Juan I Luengo, Antony N Shaw
  • Semicarbazone derivatives and their use as thrombopoietin mimetics
    Patent number: 6720345
    Abstract: Compounds of formula (I), particularly a compound of formula (Ia), are non-peptide TPO mimetics, useful in the treatment of thrombocytopenia.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: April 13, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I. Luengo, Kevin J. Duffy, Antony N. Shaw
  • Thrombopoietin mimetics
    Publication number: 20040058990
    Abstract: Invented are non-peptide TPO mimetics. also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.
    Type: Application
    Filed: June 19, 2003
    Publication date: March 25, 2004
    Inventors: Kevin J. Duffy, Juan I Luengo, Stephen G. Miller, Julian Jenkins, Alan T. Price, Antony N. Shaw
  • Regulated activation of cell-membrane receptors by metal-chelating agonists
    Publication number: 20040053299
    Abstract: Invented is a regulated activation of cell-membrane receptors by small molecule agents. Also invented is a method to render a cell-membrane receptor responsive to the activation by small molecule compounds by specific single point mutations in the transmembrane region.
    Type: Application
    Filed: June 19, 2003
    Publication date: March 18, 2004
    Inventors: Evelyn O. Delorme, Kevin J. Duffy, Peter I. Lamb, Juan I. Luengo, Shin-Shay C. Tian
  • Thrombopoietin mimetics
    Publication number: 20040019190
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: July 3, 2003
    Publication date: January 29, 2004
    Inventors: Connie J Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Anthony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Thrombopoietin mimetics
    Patent number: 6670387
    Abstract: Non-peptide TPO mimetics are disclosed, as well as a method of treating thrombocytopenia, in a mammal, including a human, in need thereof, which comprises administering to such mammal an effective amount of a selected hydroxy-1-azo-naphthalene derivative.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: December 30, 2003
    Assignees: SmithKline Beecham Corporation, Ligand Pharmaceuticals
    Inventors: Juan I. Luengo, Kevin J. Duffy, Stephen G. Miller
  • Thrombopoietin mimetics
    Patent number: 6642265
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: November 4, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I. Luengo, Kevin J. Duffy
  • G-CSF mimetics
    Patent number: 6630470
    Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: October 7, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I Luengo, Kevin J Duffy
  • Thrombopoietin mimetics
    Publication number: 20030083361
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.
    Type: Application
    Filed: September 12, 2002
    Publication date: May 1, 2003
    Inventors: Juan I Luengo, Kevin J Duffy, Alan T Price, Lihua Zhang
  • Thrombopoietin mimetics
    Patent number: 6552008
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected azo-pyrazole derivative.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: April 22, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Kevin J. Duffy, Nannan Liu, Juan I. Luengo
  • Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal
    Publication number: 20030013697
    Abstract: Invented are metal chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented metal chelated cell-surface receptor ligands.
    Type: Application
    Filed: August 12, 2002
    Publication date: January 16, 2003
    Applicant: SmithKline Beecham Corporation and Ligand Pharmaceuticals
    Inventors: Juan I. Luengo, Stephen G. Miller, John G. Gleason
  • Methods of treating thrombocytopenia
    Patent number: 6498155
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a linked cyclic polyamine derivative.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: December 24, 2002
    Assignees: SmithKline Beecham Corporation, Ligan Pharmaceuticals
    Inventors: Juan I. Luengo, Peter I. Lamb
  • Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal
    Patent number: 6413952
    Abstract: Dimeric cell-surface receptors in a subject are agonized by administering a metal chelated dimeric cell-surface receptor ligand formed by chelating a receptor binding moiety with a metal ion such as zinc, or by co-administering the receptor binding moiety and the metal ion. The binding moiety is a small organic molecule having a molecular weight of from about 100 to about 850, and metal chelation may form a symmetrical multimer such as a dimer of the receptor binding moiety. An example is bis{2,5-bis[2-benzimidazolylimino]-3a,6a-bis(2-pyridyl)-1,2,3,3a,4,5,6,6a-octahydroimidazo[4,5-d]imidazole-N,N′}-zinc(II). Dimeric cell surface receptors include granulocyte colony-stimulating factor, erythropoeitin receptor, macrophage-colony-stimulating factor, growth hormone receptor, thrombopoietin receptor, interferon alpha receptor, interferon beta receptor, tyrosine kinase receptor, insulin receptor and leptin receptor.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: July 2, 2002
    Assignees: SmithKline Beecham Corporation, Ligand Pharmaceuticals
    Inventors: Juan I. Luengo, Stephen G. Miller, John G. Gleason
  • G-CSF mimetics
    Patent number: 6346531
    Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: February 12, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Juan I Luengo, Kevin J Duffy
  • Metal complexes
    Patent number: 6280959
    Abstract: The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: August 28, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: John G. Gleason, Juan I. Luengo
  • NOVEL METAL COMPLEXES
    Publication number: 20010016568
    Abstract: Invented are zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented zinc chelated cell-surface receptor ligands.
    Type: Application
    Filed: October 30, 1998
    Publication date: August 23, 2001
    Inventors: JUAN I. LUENGO, JOHN G. GLEASON